For citations:

Mazerkina I.A., Alyautdin R.N. Lasmiditan as the First and Only Representative of a New Class of Neuroactive Anti-Migraine Medications: A Review. Safety and Risk of Pharmacotherapy. 2026;14(1):101-108. (In Russ.) https://doi.org/10.30895/2312-7821-2026-14-1-101-108